Parexel has announced it will open a new clinical trial supplies depot in China to support timely access to supplies and medications to clinical sites and patients. China continues to be a major growth market for clinical trials and for Parexel.
The China Depot is the latest addition to Parexel’s network of three Depot locations and three Coordination Hub and Distribution Centers globally. These locations are supported by 360+ colleagues in Parexel’s Clinical Trial Supplies & Logistics (CTS&L) team who have supported more than 110,000 patients across more than 500 active studies over the last 12 months.
Located in the Suzhou New District ESR Campus, the China Depot will be equipped with temperature storage (ambient, 2-8C, -20C) and secondary packaging and labeling capabilities. Parexel is making a $3 million investment in the new depot location and expects construction to be completed in November 2021 with the site fully operational by mid-2022.
Moving forward, the Pan-Asia distribution strategy for clinical supplies will be driven by the China Depot and Parexel’s Singapore Coordination Hub and Distribution Center. The new location provides critical clinical trial supplies, ancillary supplies and laboratory logistics services in the Asia/Pacific region for Parexel.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.